应功能有机分子化学国家重点实验室邀请，美国The University of Texas at El Paso朱耀球博士来我校进行交流并做学术报告，欢迎感兴趣的师生参加。

报  告 人：Dr. Yaoqiu Zhu（朱耀球 博士）

报告题目：The Chemistry of a Blockbuster Antithrombotic   Medicine, Clopidogrel (Plavix®)

报告时间：2018年6月4日（星期一）上午 10:30

报告地点：第二化学楼101学术报告厅

报告人简介

Dr. Zhu obtained his B.S. of Chemistry in 2001 at Peking University in Beijing, China. Under the supervision of Prof. Richard B. Silverman (inventor of Pfizer’s blockbuster drug Lyrica) in the Department of Chemistry at Northwestern University, he conducted doctoral research on enzyme chemistry and got his Ph.D. in 2006. With a strong interest in drug discovery, he then joined Abbott Laboratories/AbbVie as a senior research scientist. Dr. Zhu conducted “structure and drug-like property relationship” studies for over 20 internal R&D projects including a program that has eventually yielded the recently approved HCV drug Viekira Pak. After working at Abbott for over two years, Dr. Zhu resigned and founded his own contract research company, MetabQuest. He independently built a drug metabolism and medicinal chemistry lab in Beijing, China. He and his team have worked with pharmaceutical companies and research institutes on various medicinal chemistry projects and preclinical studies. In addition, Dr. Zhu’s lab has participated in several translational drug discovery research collaborations involving Harvard Medical School, University of Pittsburgh, Northwestern University, China Pharmaceutical University, Cambria Biosciences, etc. To pursue the long-term goal of becoming a medicinal chemistry professor, since 2012, Dr. Zhu has closed his company and devoted his lab to academic research projects, including “Investigation of the clinical drawbacks of Plavix (Sanofi & BMS) and discovery of novel antiplatelet agents”. In the fall of 2015, he started a tenure-track assistant professor position at Department of Chemistry and Biochemistry in the University of Texas at El Paso. Dr. Zhu’s research focuses on clinic-oriented and mechanism-driven medicinal chemistry.